In intestinal L-cells and neurons of the NTS, a predominance of PC1/3 expression, GLP-1, oxyntomodulin, and GLP-2 are seen as physiologically relevant (Tucker et al., 1996
It gives us pause to say for an average employer group out there if youre investing in this medication for your employees, dont expect to see a return in year one. According to Joseph Leach, M.D., Senior Vice President and Chief Medical Officer at Prime, We will need results of ongoing, multi-year studies to see if this treatment has downstream impacts on other health conditions, including cardiovascular events and diabetes development prevention, which are key benefits to weight loss management
Zhu Y, Jameson E, Crosatti M, et al
Douglas Twenefour, Head of Care at Diabetes UK, said: We fully support the instruction that GLP-1 medications should not be prescribed off-label under any circumstances while there is any shortage impacting people with type 2 diabetes
Y., Martino, L